PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis

(2018) Lu Li et al.   Scientific Reports

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL

(2017) Qian-Yun Shi et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

(2017) Xiaohong Zhao et al.   Nature Communications

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

(2017) Tri Nguyen et al.   Oncotarget

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease

(2016) B. Chapuy et al.   BLOOD

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

(2016) Rossella Marullo et al.   CELL CYCLE

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival

(2016) Daibiao Xiao et al.   MOLECULAR CELL

A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

(2016) Daniel Dauch et al.   NATURE MEDICINE

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells

(2015) Yongqiang Chen et al.   CANCER BIOLOGY & THERAPY

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

(2015) Clémentine Sarkozy et al.   LANCET ONCOLOGY

Understanding the Polo Kinase machine

(2015) V Archambault et al.   ONCOGENE

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

(2015) Ariosto Silva et al.   Jove-Journal of Visualized Experiments

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

(2014) Anamarija M. Perry et al.   BRITISH JOURNAL OF HAEMATOLOGY

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

(2014) B T Gjertsen et al.   LEUKEMIA

Polo-like kinases: structural variations lead to multiple functions

(2014) Sihem Zitouni et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

MYC Degradation

(2014) A. S. Farrell et al.   Cold Spring Harbor Perspectives in Medicine

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

(2013) Xin Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy

(2013) J. Tan et al.   Cancer Discovery

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

(2012) Xinwei Zhang et al.   CANCER CELL

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC and Aggressive B-cell Lymphomas

(2011) Graham W. Slack et al.   ADVANCES IN ANATOMIC PATHOLOGY

Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

(2011) A. Hoglund et al.   CLINICAL CANCER RESEARCH

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

(2011) P. S. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

(2010) J. den Hollander et al.   BLOOD

Double-hit B-cell lymphomas

(2010) S. M. Aukema et al.   BLOOD

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY